PCM

Description of the project

The overall objective of the project

Personalised cancer medicine (PCM) is based on the characteristics and circumstances of the individual — genes, lifestyle, medical history, etc. — and uses this knowledge to tailor and target cancer treatment. The personalised approach benefits patients at several stages: in prevention and early diagnosis, in treatment and care, and for cancer survivors, where late effects, prevention and detection of recurrence are central. The key aim of the project is to ensure a broader implementation of personalised cancer medicine across EU Member States, thereby making personalised cancer medicine more accessible to a greater number of people — both here in Denmark and throughout the rest of the EU. The project is part of EU’s major health initiative, EU4Health, which was launched in the wake of the COVID-19 pandemic. The programme entails substantial investments to strengthen healthcare systems, improve access to advanced treatments, and facilitate the sharing of knowledge and tools across national borders. 

This joint action focuses on three areas:

1. personalised prevention and early detection
2. personalised ‘medicine’
3. personalised follow-up and tertiary prevention.

Part of the project is also several more practical pilots, which addresses themes such as using and implementing liquid biopsies, digital innovation for remote monitoring etc.  

The role of Lillebaelt Hospital

Lillebælt Hospital has been designated as competent authority for Danish participants and thereby coordinating and ensuring strategic ground in Danish activities. In addition to Lillebælt Hospital several other Danish hospitals and institutions take part of the project: Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Zealand University Hospital, Copenhagen University Hospital and the Health Innovation Centre of Southern Denmark.

Lillebælt Hospital also holds the role as lead of Work Package 10 about ‘survivorship’. In this work package, a consortium of partners from across the EU collaborates to improve the care and support provided to cancer survivors. The work encompasses a broad portfolio of activities ranging from mapping the current use of liquid biopsies in clinical practice to addressing long-term treatment effects. Throughout the process, emphasis is placed on patient-centered interventions, ensuring equitable access, and developing practical, implementable guidelines.

Read more about the Office of Health and Partnerships.